INREBIC
Drug
Celgene Corporation
Total Payments
$3.0M
Transactions
2,028
Doctors
1,092
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $476,762 | 8 | 5 |
| 2023 | $59,914 | 15 | 5 |
| 2022 | $166,067 | 66 | 14 |
| 2021 | $617,415 | 271 | 170 |
| 2020 | $1.7M | 1,668 | 958 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.3M | 104 | 74.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $443,582 | 165 | 14.6% |
| Consulting Fee | $151,032 | 75 | 5.0% |
| Travel and Lodging | $90,438 | 127 | 3.0% |
| Food and Beverage | $45,739 | 1,495 | 1.5% |
| Education | $27,545 | 60 | 0.9% |
| Grant | $12,500 | 1 | 0.4% |
| Charitable Contribution | $10,000 | 1 | 0.3% |
Payments by Type
Research
$2.3M
104 transactions
General
$780,836
1,924 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy & Safety Study of Fedratinib in Subjects w/ DIPSS-Intermediate or High-Risk PMF, post-PV MF, or post-ET MF & Previously Treated w/ Ruxolitinib incl. Sub-study w/ concomitant Luspatercept for anemia | Celgene Corporation | $598,693 | 0 |
| A phase 2 study of fedratinib in myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL) | Celgene Corporation | $383,181 | 0 |
| A Phase 3b, Multicenter, Single-Arm, Open-Label Ef | Celgene Corporation | $320,497 | 0 |
| A Phase 1, Open-Label, Single Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Fedratinib in Subjects with Moderate and Severe Hepatic Impairment Compared with Healthy Subjects (BMS Study Number: CA054-P06) | Celgene Corporation | $276,972 | 0 |
| A Phase 1 Open-label, Single-dose Study to Assess | Celgene Corporation | $241,114 | 0 |
| (FEDR-CP-002 (PMC)) A Phase 1, Open-label, 2-part Study to Evaluate the Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects (BMS Study Number: CA054-P07) | Celgene Corporation | $179,184 | 0 |
| A Phase 3b, Multicenter, Single-Arm, Open-Label Ef - A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-Risk Primary Myelofi | Celgene Corporation | $89,838 | 0 |
| Phase I Trial of Fedratinib in Combination with Decitabine in Patients with Myeloproliferative Neoplasms in Accelerated and Blast Phase | Celgene Corporation | $72,736 | 0 |
| A Phase 1 Open-label, Single-dose Study to Assess - A Phase 1 Open-label, Single-dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Fedratinib in Subjects with Moderate and Severe Hepatic Impairment Compared with Healthy Subjects | Celgene Corporation | $30,512 | 0 |
| A Phase 1, Open-Label, Single Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Fedratinib in Subjects with Moderate and Severe Hepatic Impairment Compared with Healthy Subjects | Celgene Corporation | $26,060 | 0 |
| (FEDR-CP-005) BE Study - A Phase 1, Open-label, Single-center, 2-part Crossover Study to Evaluate the Relative Bioavailability of Fedratinib When Administered as Contents of Capsules Dispersed in a Nutritional Supplement Orally or Via Nasogastric Tube, or | Celgene Corporation | $24,689 | 0 |
| A Phase I/II GVHD Prevention trial combining fedratinib with sirolimus and post-transplant cyclophosphamide for allogeneic HLA matched donor using peripheral blood stem cells. | Celgene Corporation | $16,032 | 0 |
| A Phase 1/2, Multicenter, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System) | E.R. Squibb & Sons, L.L.C. | $2,160 | 2 |
| A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms | Celgene Corporation | $768.00 | 0 |
| A Phase 3b, Multicenter, Single-Arm, Open-Label Ef - A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-Risk Primary Myelofibrosis | Celgene Corporation | $590.00 | 0 |
| A Phase 1, Open-label Study to Evaluate the Influence of Fedratinib on the Pharmacokinetics of Transporter Probe Substrates (Digoxin, Rosuvastatin, and Metformin) in Healthy Adult Subjects | Celgene Corporation | $122.22 | 0 |
Top Doctors Receiving Payments for INREBIC
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Irene Hutchins | — | La Quinta, CA | $2.3M | 107 |
| , M.D | Medical Oncology | Bethesda, MD | $82,951 | 28 |
| , MD | Hematology & Oncology | Jersey City, NJ | $57,114 | 39 |
| Bart Scott | Medical Oncology | Seattle, WA | $47,930 | 28 |
| , MD | Hematology & Oncology | Minneapolis, MN | $35,656 | 26 |
| , MD | Hematology & Oncology | New Orleans, LA | $32,019 | 21 |
| , MD | Medical Oncology | Orange, CA | $24,309 | 15 |
| , MD | Hematology & Oncology | San Antonio, TX | $23,888 | 8 |
| , MD | Internal Medicine | Orlando, FL | $21,803 | 14 |
| , MD | Internal Medicine | Ann Arbor, MI | $21,758 | 7 |
| , MD | Medical Oncology | Dallas, TX | $21,028 | 10 |
| , MD | Hematology & Oncology | San Diego, CA | $18,349 | 10 |
| , MD | Internal Medicine | Stony Brook, NY | $16,767 | 11 |
| , M.D | Internal Medicine | Duarte, CA | $16,089 | 17 |
| , M.D | Hematology & Oncology | Carmel, IN | $14,762 | 16 |
| , M.D | Internal Medicine | Gardena, CA | $14,173 | 8 |
| , M.D | Internal Medicine | Tampa, FL | $13,857 | 7 |
| , M.D | Hematology & Oncology | Memphis, TN | $12,569 | 10 |
| , M.D | Specialist | Columbia, MD | $11,744 | 6 |
| , M.D | Hematology & Oncology | Birmingham, AL | $11,359 | 7 |
| , M.D | Hematology | Hawthorne, NY | $11,274 | 7 |
| , MD | Hematology & Oncology | Atlanta, GA | $11,077 | 8 |
| , M.D | Hematology & Oncology | Omaha, NE | $11,027 | 7 |
| , MD | Hematology & Oncology | Orlando, FL | $10,933 | 11 |
| , MD | Hematology & Oncology | New York, NY | $10,915 | 4 |
Ad
Manufacturing Companies
- Celgene Corporation $3.0M
- E.R. Squibb & Sons, L.L.C. $54,196
Product Information
- Type Drug
- Total Payments $3.0M
- Total Doctors 1,092
- Transactions 2,028
About INREBIC
INREBIC is a drug associated with $3.0M in payments to 1,092 healthcare providers, recorded across 2,028 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2020 to 2024. In 2024, $476,762 was paid across 8 transactions to 5 doctors.
The most common payment nature for INREBIC is "Unspecified" ($2.3M, 74.3% of total).
INREBIC is associated with 16 research studies, including "A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy & Safety Study of Fedratinib in Subjects w/ DIPSS-Intermediate or High-Risk PMF, post-PV MF, or post-ET MF & Previously Treated w/ Ruxolitinib incl. Sub-study w/ concomitant Luspatercept for anemia" ($598,693).